Abstract 1739P
Background
According to the American Cancer Society, lung cancer is the leading cause of cancer-related deaths globally, and tobacco use is the 1ry cause of the disease. The association between tobacco use and lung cancer is well recognized, with smoking cigarettes accounting for approximately 85% of all lung cancer cases. Despite significant public health efforts to reduce tobacco use, it remains a prevalent issue, with an estimated 14% of the U.S. adult population being current smokers. Therefore, there is a continued need to investigate the relationship between tobacco use and lung cancer to better establish public health interventions and policies that can reduce the burden of this deadly disease.
Methods
Using the CDC multiple causes of death database (ICD-10 revision codes), we identified all patients with history of tobacco use who died of lung cancer (C34.x registered as the underlying cause of death) in Caucasian, African American, Asian, American Indian races, between 1999 and 2020 in the United States. Age-adjusted mortality rates were calculated per 1,000,000 persons (PMP), standardized to the U.S. census data from 1999, and stratified by gender.
Results
Between 1999 and 2020, 1,084,140 deaths were due to lung cancer in persons with history of tobacco use (age-adjusted mortality= 144.6 PMP). We identified a total of 970,370 Caucasian, 96,001 African American, 11,279 Asian, and 6,490 American Indian deaths in each population (total age-adjusted mortality was 151.5 PMP, 129.5 PMP, 38.3 PMP, and 117.7, respectively). Over 21 years, age-adjusted mortality increased by 782% in Caucasians (19.5 PMP in 1999 to 152.4 PMP in 2020), 575% in African Americans (21.2 PMP in 1999 to 121.9 PMP in 2020), 724% in Asians (5 PMP in 1999 to 36.2 PMP in 2020), and 351% in American Indians (27.2 PMP in 1999 to 95.5 PMP in 2020).
Conclusions
The study's results show a significant and consistent rise in the mortality rates of tobacco-related lung cancer among all ethnicities, ranging from 351% in American Indians to 782% in Caucasians. These findings emphasize the urgent need for effective public health interventions and policies that can address the destructive impact of tobacco use on lung cancer mortality across all racial groups in the U.S.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1890P - Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
Presenter: Christopher Darr
Session: Poster session 23
1891P - Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
Presenter: Renee Saliby
Session: Poster session 23
1892P - A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
Presenter: Rana McKay
Session: Poster session 23
1895P - Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
Presenter: Sara Elena Rebuzzi
Session: Poster session 23
1896P - Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab+ipilimumab (N+I): A real-world study
Presenter: Tom Geldart
Session: Poster session 23
1897P - Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Presenter: Francesco Massari
Session: Poster session 23
1899P - Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)
Presenter: Georges Gebrael
Session: Poster session 23
1900P - Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the national cancer database (2004-2020)
Presenter: ALINA BASNET
Session: Poster session 23